NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2026)

NewAmsterdam Pharma has reported Other Non-Current Assets for 4 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Other Non-Current Assets changed N/A year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (changed N/A YoY) and the FY2023 annual result came in at $35000.0, down 77.56% from the prior year.
• Other Non-Current Assets grew to $2.6 million in Q1 2026 per NAMS's latest filing, from $8000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $2.6 million in Q1 2026 and troughed at $101.27 in Q2 2023.
• A 4-year average of $465509.6 and a median of $25500.0 in 2023 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets tumbled 76.5% in 2023, then surged 7799.68% in 2024.
• Over 4 years, Other Non-Current Assets stood at $148956.1 in 2022, then sank by 76.5% to $35000.0 in 2023, then sank by 77.14% to $8000.0 in 2024, then jumped by 32212.5% to $2.6 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.6 million, $8000.0, and $16000.0 for Q1 2026, Q2 2024, and Q1 2024 respectively.